
|Articles|June 5, 2006
GPhA lauds FDA approval of Omnitrope
The Generic Pharmaceutical Association (GPhA) called the approvalof Sandoz Pharmaceutical's Omnitrope human growth hormone (HGH) asignificant first step in bringing more affordablebiopharmaceuticals to the U.S. marketplace. GPhA president/CEOKathleen Jaeger said that FDA's Omnitrope decision demonstratesthat sound science exists to support the approval of genericbiopharmaceuticals.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
2
Expert Discusses Cannabinoid Adverse Effects | ASHP Midyear 2025
3
Pharmacists Must Consider Benefits and Risks for GLP-1 Medication for Pediatric Patients | ASHP Midyear 2025
4
Centralized IV Compounding Drives Pharmacy Savings, Efficiency | ASHP Midyear 2025
5



































































































































